NCT04248348

Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients

Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 600 (estimated)
• Sponsor: Metaxa Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

During MeTHOS study will be collected Real World Data the clinical practice regarding Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or chemotherapeutical treatment, for one year following the protocol initiation date. Specifically focus will be on the following: * Number of thrombotic events * Anti-thrombotic management dosage \& duration * Any bleedings related to anticoagulation * Patients' adherence and compliance

Conditions

• Thrombosis
• Solid Cancer

Interventions

Type	Name	Description
DRUG	Low Molecular Weight Heparin	Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)

Timeline

• Start date: 2018-12-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2020-01-30
• Last updated: 2020-01-30

Locations

1 site across 1 country: Greece